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The rapid decline in endogenous estrogen production that occurs during menopause is associated with signiﬁcant bone loss and
increased risk for fragility fracture. While hormone therapy (HT) is an eﬀective means to re-establish endogenous estrogen levels
and reduce the risk of future fracture, its use can be accompanied by undesirable side eﬀects such as stroke and breast cancer. In
this paper, we revisit the issue of whether HT can be both safe and eﬀective for the prevention of postmenopausal bone loss by
examining standard and alternative doses and formulations of HT. The aim of this paper is to continue the dialogue regarding the
beneﬁts and controversies of HT with the goal of encouraging the dissemination of-up-to date evidence that may inﬂuence how
HT is viewed and prescribed.
1.Introduction
Osteoporosis is a skeletal disorder characterized by low bone
mass and low bone quality which leads to compromised
bone strength and an increased risk of fracture [1]. The
prevalence of osteoporosis in the United States and Canada
is high, with 10 million Americans and 2 million Canadians
aﬀected with this disease. Several more millions, although
not osteoporotic, suﬀer from low bone mass and will
experience a fragility fracture in their lifetime [1, 2]. Along
with its signiﬁcant consequences to morbidity and mortality,
osteoporosis has an annual cost of 20 billion dollars to the
American and Canadian health care systems combined and,
it is expected that this economic burden will rise due to
rapidly aging populations [2, 3].
The decline in endogenous estrogen production that
occurs during menopause has important implications for
skeletal health because estrogen plays a major role in
the development and maintenance of the human skeleton
throughoutthelifespan.Inpostmenopausalwomen,reduced
levels of endogenous bioavailable estrogen are associated
with lower bone mineral density (BMD) and higher risk for
fragility fractures [4–7]. The repletion of endogenous estro-
gen through the use of hormone therapy (HT) eﬀectively
prevents postmenopausal bone loss and reduces the risk of
fragility fractures [8–12].
While the beneﬁt of HT, particularly conjugated equine
estrogens (CEEs), on the prevention and treatment of
postmenopausal osteoporosis and related fracture has been
demonstrated, its eﬀects on the health of other estrogen-
sensitive tissues such as the uterus and breast must
be carefully considered. In many circumstances, estrogen
induces proliferation of the uterine and breast tissues [13–
15]. In addition, postmenopausal women are at a higher
risk for coronary heart disease (CHD) and breast cancer
than their premenopausal counterparts, and the eﬀects of
HT may modify these risks. Moreover, estrogen has been
shown to modulate vascular function; however, its eﬀect on
cardiovascular health is rather controversial. Evidence from
observational trials [16, 17] suggests that HT is associated
with a lower risk of CHD; however, subsequent data from
two large randomized clinical trials (RCTs), the Heart and
Estrogen/Progestin Replacement Study (HERS), and the
Women’s Health Initiative (WHI) trial did not conﬁrm
these beneﬁts [9, 10, 18]. The HERS reported no beneﬁt
[18] from the use of HT, and the WHI study reported
a signiﬁcantly greater number of cardiovascular events in2 Journal of Osteoporosis
women taking HT compared to women taking placebo [9,
10]. Despite important limitations including high drop-out
rates in the WHI, major consequences of the ﬁndings from
WHI were a signiﬁcant drop in HT prescription and use
worldwide, with a concomitant increase in the prescription
and use of alternative therapies (e.g., bisphosphonates) for
the treatment of postmenopausal bone loss, for which their
long-term consequences remain unknown [19, 20]. Many
women were also left with little option for the relief of
symptoms associated with the onset of menopause.
Study ﬁndings including secondary analysis of the WHI
have shown that HT is safe in younger postmenopausal
women for the treatment of vasomotor symptoms and
for the prevention of osteoporosis [21]. In fact, consensus
statements from the North American and International
Menopause Societies also support the notion that HT use
maybesaferinyoungerpostmenopausalwomen(aged50-59
years, or fewer than 10 years after the onset of menopause)
[22–24]. In addition, RCTs are underway to conﬁrm the
safety of HT in younger postmenopausal women [25].
Nevertheless, long-term studies are needed to determine
whetherlowerdosesofHTwithalternativemodesofdelivery
are associated with fewer side eﬀects compared to the
standard HT formulations.
In this paper, we revisit the usefulness of estrogen for
the prevention and treatment of postmenopausal bone loss
by reviewing the literature on its eﬀectiveness at attenuating
bone loss and risk of fracture and its side eﬀects, in the
context of alternative formulations and lower doses than
traditionally prescribed. Through continuous dialogue and
emerging evidence, the question of whether HT should be
recommended to postmenopausal women is shifting to the
question of which type of HT can be prescribed for the
treatment of menopausal-related symptoms including bone
loss, particularly in younger postmenopausal women.
2.Effects ofStandardHTon Skeletal Health
duringPostmenopause
The most popular HT formulation prescribed to post-
menopausal women is the CEE derived from urine of preg-
nant mares [26–28]. Medroxyprogesterone acetate (MPA) is
conventionally added to CEE for women with intact uteri
but, for hysterectomized women, CEE alone is used for the
treatment of postmenopausal-related conditions including
loss of bone mass. CEE, as indicated by its name, is itself
made up of several conjugated forms of estrogen, mainly
estrone sulfate and equilin sulfate. The most prescribed
dose of CEE is 0.625mg/d because this is the dose that
alleviates postmenopausal-related symptoms in the majority
of women that endure ovarian failure [29]. Other forms of
estrogen in HT include esteriﬁed estrogen, ethinyl estradiol,
17β-estradiol, estradiol acetate, and estropipate. Norethin-
drone, levonorgestrel, and progesterone are the commonly
used forms of progestogens in HT.
Unquestionably, HT during postmenopause improves
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in nonvertebral sites including the hip (Table 1)[ 8–10, 12,
20, 31]. Observational studies have reported decreases of up
to 71% in fracture risk with HT use [12, 20]. In a subgroup
(n = 138,737) of postmenopausal women from the Million
Women Study, current use of HT was associated with a 38%
decrease in risk for total fractures, regardless of the type,
dose, or delivery method of HT [20]. Similar observations
were reported in other prospective cohorts including the
Study of Osteoporotic Fractures trial, whereby current use
of HT was associated with 34% and 38% decreases in risk for
all nonspinal and hip fractures, respectively [31]. Moreover,
current users that started HT within 5 years of menopause
had a 50% decrease in risk for all nonspinal fractures and a
71% decrease in risk of hip fractures [31].
Similar to observational studies, RCTs have conﬁrmed
the protection of HT against fracture risk, albeit at more
modest levels (∼30%) (Table 1)[ 9, 10, 30]. The largest
RCT reporting the eﬀects of HT on fracture risk is the
WHI.Thistrialwasdesignedprimarilytodeterminewhether
daily use of 0.625mg CEE plus 2.5mg MPA (for nonhys-
terectomized women) or 0.625mg CEE alone (for hysterec-
tomized women) reduces CHD in healthy postmenopausal
women [9, 10]. Both the combination (CEE + MPA) and
alone (CEE) arms were stopped early, after a mean of 5.2
and 6.8 years, respectively, because the number of observed
side eﬀects was deemed unacceptable. Nevertheless, CEE +
MPA use was associated with a 34% decrease in risk for hip
fractures and a 26% decrease in risk for total fractures [9].
Use of CEE alone was associated with a 39% decrease in risk
forhip fracturesand a 30% decrease in risk fortotal fractures
(Table 1)[ 10].
While the positive eﬀects of HT on bone health in
postmenopausal women have been widely shown in both
observational and clinical trials, the side eﬀects popularized
by its use in the WHI trial have resulted in dramatic
decreases in its prescription and use worldwide [19, 26,
32]. Few women have been left with the option for HT
use for simultaneously alleviating vasomotor symptoms and
preserving bone tissue; however, the decision to discontinue
HT may have been somewhat misguided.
3. SideEffects Associatedwith the Use of
StandardHT
The potential for estrogen to modulate the health of
many tissues in the body is based largely on the fact that
estrogen receptors are located in both reproductive and
nonreproductive tissues [33]. Thus, in addition to its ability
to reduce vasomotor symptoms, vaginal atrophy and prevent
postmenopausal bone loss, HT has the ability to modulate
the health of many other tissues including the breast, liver,
kidneys and cardiovascular tissues. Since postmenopausal
women are at an increased risk for CHD and breast cancer,
it is prudent to determine the safety proﬁle of HT in these
tissues.
Described as an estrogen-deﬁciency disease, menopause
was previously portrayed as a catalyst for the development
of other diseases such as CHD, due to the dramatic decline
in endogenous estrogen production [28, 34]. Evidence fromJournal of Osteoporosis 3
Table 1: Selected studies on the eﬀect of hormone therapy on bone metabolism in postmenopausal women
Study Name Study Type
Sample Size,
Mean Age in
Years (Range),
and Years since
Menopause
Type of
Therapy Dose Treatment Duration Results for BMD, BMC, or
Fracture Risk
WHI
Estrogen plus
Progesterone
Trial [9]
RCT
16608,
63 (50–79),
>6m o n t h s( >12
months for
50–54 years old)
CEE + MPA
or placebo
CEE: 0.625mg/d
MPA: 2.5mg/d
(continuous)
Stopped after a mean of
5.2 years due to increases
in breast cancer, stroke,
CHD
HR, 0.66 [0.45–0.98] for
incidence of hip fractures.
HR, 0.76 [0.69–0.85] for
incidence of total fractures.
WHI
Estrogen
alone Trial
[10]
RCT
10739,
64 (50–79),
previously
hysterectomized
CEE or
placebo CEE: 0.635mg/d
Stopped after a mean of
6.8 years due to increases
in stroke
HR, 0.61 [0.41–0.91] for
incidence of hip fractures.
HR, 0.70 [0.63–0.79]for
incidence of total fractures.
WISDOM
Trial [30] RCT
4385,
63 (50–69),
>12 months or
previously
hysterectomized
CEE,
CEE + MPA,
or placebo
CEE: 0.635mg/d
MPA: 2.5mg/d
(continuous) or
5.0mg/d (sequential)
Stopped after a mean of
11.9 months due to
adverse ﬁndings inWHI
[8]
HR, 0.69 [0.46-1.03] for
incidence of osteoporotic
fractures.
PEPI Trial [8]R C T
875,
56 (45–64),
1t o<10 years
(either naturally
or surgically)
CEE,
CEE + MPA,
CEE + MP, or
placebo
CEE: 0.625mg/d
MPA: 2.5mg/d
(continuous) or
10mg/d (sequential)
MP: 200mg/d
(sequential)
3 years
3.5–5.0% increase in LV
BMD;
1.7% increase in hip BMD
with these doses.
Danish Nurse
Cohort Study
[12]
Prospective
14015,
60 (≥50),
Years since
menopause not
provided
All types
(e.g., CEE,
E2)a n d
delivery
methods (ex:
oral,
transdermal)
All Doses (ex: CEE,
>0.625mg/d or
≤0.625mg/d; E2,
>1mgor≤1mgoral;
E2, >50μgo r≤50μg
transdermal); Various
doses of MPA and NA
as continuous or
sequential regimes
Mean years of follow-up:
not reported (Range:
0–6 years)
HR, 0.69 [0.50–0.94] for
incidence of hip fractures
with ever users.
Million
Women
Study [20]
Prospective
138737,
Mean age in
years not
provided
(50–69),
Years since
menopause not
provided
All types (ex:
CEE, E2)a n d
delivery
methods (ex:
oral,
transdermal)
All Doses (ex: CEE,
>0.625mg/d or
≤0.625mg/d; E2,
>1mgor≤1mgoral;
E2, >50μgo r≤50μg
transdermal); Various
doses of MPA and NA
as continuous or
sequential regimes
Mean years of follow-up:
2.8 (Range: 1.9–3.9
years)
RR, 0.62 [0.58–0.66] for
incidence of fracture with
current users.
RR, 1.07 [0.99–1.15] for
incidence of fracture with
past users.
SOF Trial
[31] Prospective
9704,
70–72 (>65),
2 years before
onset of
menopause to
>10 years
All types of
oral
preparations
All doses of oral
preparations
Mean years of follow-up:
2.5 (Range: 0.02–6.5
years)
RR, 0.60 [0.36–1.02] for
incidence of hip fractures
with current users.
RR, 0.66 [0.54–0.80] for
incidence of all nonspinal
fractures with current
users.
RR, 0.29 [0.09–0.92] for
incidence of hip fractures
with current users who
started HT within 5 years
of menopause.
RR, 0.50 [0.36–0.70] for
incidence of all nonspinal
fractures with current users
who started HT within 5
years of menopause.
RCT: Randomized Control Trial, CEE: Conjugated Equine Estrogen, MPA: Medroxyprogesterone Acetate, MP: Micronized Progesterone, NA: Norethisterone
Acetate, E2:1 7 β-estradiol, BMD: Bone Mineral Density, LV: Lumbar Vertebra, HR: Hazard Ratio, and RR: Relative Risk.4 Journal of Osteoporosis
observational trials indicated HT as a postmenopausal
therapy with many health beneﬁts, and that it was marketed
to prolong youth and libido, resulting in its popularity to
quickly expand worldwide [28]. To validate the notion that
HT supports health during menopause and prevents the
development of side-eﬀects associated with other diseases,
two large trials, the HERS and WHI, were carried out on
a combined 30110 postmenopausal women in multicentre,
randomized, double-blind, placebo-controlled designs [9,
10, 18]. The HERS trial was the ﬁrst large RCT to evaluate
whether daily use of 0.625mg CEE plus 2.5mg MPA alters
the risk of CHD events in 2763 postmenopausal women
with established CHD [18]. After an average follow-up of 4.1
years, HT did not confer protection against cardiovascular
events (nonfatal myocardial infarction or CHD death), and
its use was associated with higher venous thromboembolic
events compared to placebo. Interestingly, HT use was
associated with higher risk for CHD events during the ﬁrst
yearoftreatment,however,inthefourthandﬁfthyearsofthe
trial, its use was associated with lower risk for CHD events
compared to placebo. Thus, the HERS trial demonstrated
that the use of HT does not provide an overall beneﬁt to
cardiovascular health in women that have never used HT
but it may provide beneﬁt to cardiovascular health in current
users that continue HT [18]. Subsequently, the WHI, which
was the largest RCT to examine the eﬀect of HT on the
prevention of CHD, demonstrated that HT is associated with
increased risk of CHD, stroke, venous thromboembolism,
and breast cancer in the combination group and stroke in
the estrogen alone group. The WHI ﬁndings resulted in
early termination of the trial and subsequently widespread
discontinuation of HT among postmenopausal women
worldwide [9, 10, 26, 35].
The reasons for inconsistent ﬁndings among previous
observationaltrialsandtheHERSandWHItrialsmaybedue
to diﬀerences in subject characteristics and inherent designs.
For example, observational studies that have investigated
the safety of HT have included younger postmenopausal
subjects; however, the HERS and WHI trials consisted of
mainly older postmenopausal women. In addition, obser-
vational studies can be subjected to unknown confounders
that inﬂuence the outcome variable and are susceptible to
a number of biases including sampling bias and admission
rate bias, whereas RCTs can experience inadequate random-
ization,unblinding,andlossofsamplingunits—allofwhich
can inﬂuence the outcome variable [36]. Nevertheless, since
RCTs by design are superior compared to observational
studies, the WHI study would inevitably have the greatest
impact on HT recommendations for the postmenopausal
population.
4. Limitationsof the WHI
Important limitations of the WHI have become the focus of
subsequent dialogue and have stimulated experts to question
whether the WHI ﬁndings can be generalized to all post-
menopausal women receiving various forms of HT. These
limitations, which will be brieﬂy discussed, include (i) a high
loss of subjects, (ii) an older and healthy postmenopausal
population included as subjects, and (iii) the investigation of
one formulation, dose, and delivery method of HT.
(i) The WHI suﬀered from a large loss of subjects. 42%
of the subjects in the combination arm and 53.8% in the
estrogen alone arm dropped out of the WHI resulting in
reduced power of its design. The implication of a high drop-
out rate may be an underestimation of observed eﬀects,
whether negative (ex: CHD and breast cancer) or positive
(ex: fracture) [9]. However, being that losses in subjects
are rarely a random occurrence [36], it is too simplistic
to assume that the observed eﬀects are merely an under-
estimation of what would have occurred if an appropriate
number of subjects remained in the study throughout its
total duration.
(ii) The WHI enrolled into its trial mostly older and
healthypostmenopausalwomen.WhiletheWHIreportedan
unfavorable risk-to-beneﬁt ratio, this study was conducted
in a predominantly older and asymptomatic menopausal
population, many of which who were 13–15 years past the
onset of menopause. However, HT is targeted primarily to
younger and more recently postmenopausal women for the
treatment of menopausal symptoms including hot ﬂushes,
vaginal dryness, and decreased libido. Thus, there is a clear
disconnect between the conventional target group of HT
and the subjects from the WHI in terms of age and health
status, and the question of whether similar ﬁndings would
be observed in a younger postmenopausal population still
remains.
Observational studies point toward the notion that time
sincemenopausemaybeanimportantfactoronriskofCHD
and other side eﬀects of HT [24, 37]. Posthoc subgroup
analysis by Rossouw et al. [21] of younger postmenopausal
women (aged 50–59) in the WHI trials detected a tendency
for HT to reduce the risk of CHD and total mortality.
Further analysis of the WHI study by Manson et al. [38]
determined that CEE alone resulted in lower coronary-
artery calciﬁcation compared to placebo in the younger
postmenopausal women aged 50–59 years. Nonetheless,
these subsequent analyses were not adequately powered,
especially in women aged 50–54 or closer to the onset of
menopause (<5y e a r s )[ 21]. Thus, diﬃculties remain in
drawing clear conclusions from the secondary analyses of the
WHI. While data from observational trials have shown that
HT is protective against CHD, mortality, and other diseases
in younger postmenopausal women, RCTs are underway
to determine whether these previous ﬁndings can indeed
be conﬁrmed [25]. In the meantime, in March 2008, the
International Menopause Society held a global summit to
addresstheactualversusperceivedrisksofHTuseinyounger
postmenopausal women [24]. Through the scrutiny of vast
empirical evidence, this summit resulted in a consensus that
there may be a “window of opportunity” whereby HT is
safe in women that are closer to the onset of menopause
(<10 years). Nevertheless, current opinion regarding the use
of HT for the treatment of vasomotor symptoms and for
the prevention of osteoporosis during the postmenopause is
that the lowest eﬀective dose should be used for the shortest
duration possible.Journal of Osteoporosis 5
(iii) Only two formulations of HT were investigated
in the WHI, CEE + MPA (0.625mg/d + 2.5mg/d) for
postmenopausal women with an intact uterus or CEE alone
(0.625mg/d) for postmenopausal women who had under-
gone hysterectomy. Both these formulations were provided
as an oral tablet. Whether alternative formulations of HT,
such as low-dose transdermal HT, result in fewer side eﬀects
than those observed with the HT used in the HERS or WHI
trials is yet to be determined. However, compelling evidence
points towards an advantage for lower doses of HT through
the transdermal delivery method compared to oral standard
dose HT.
5. Effects of Lower Doses andTransdermalHT
on Skeletal Health duringPostmenopause
The most commonly prescribed HT for postmenopausal
women is oral CEE (0.625mg/d) alone or in combination
with MPA (2.5mg/d). In pursuit of the lowest eﬀective
dose for the attenuation of menopausal-related conditions
including bone loss, several studies chose to examine doses
that are three-quarters, half, and a quarter of the standard
dose. In addition, alternative modes of delivery, such as
the transdermal patch, are being studied because evidence
indicates that they are associated with fewer side eﬀects
compared to the oral standard dose formulations. For the
purpose of this paper, 0.3mg and 0.45mg CEE, along with
25μgt r a n s d e r m a l1 7 β-estradiol are considered low-dose HT
while 14μgt r a n s d e r m a l1 7 β-estradiol is considered ultra-
low-dose HT.
Results from a number of trials have shown that lower
doses of HT are eﬀective in improving BMD in the hip
and lumbar spine (Table 2)[ 39–47]. In a substudy (n
= 822) of the Women’s Health, Osteoporosis, Progestin,
Estrogen (HOPE) trial, standard and lower doses of orally
administered CEE alone or in combination with MPA
resulted in signiﬁcant improvements from baseline (1.33–
3.46%) in spine and hip BMD, as well as biochemical
markersofboneturnoverinhealthypostmenopausalwomen
within 4 years since the onset of menopause [40]. These
improvements contrasted from the placebo group, which
experienced signiﬁcant losses in spine BMD and total body
bone mineral content. While CEE alone at the standard dose
resulted in higher gains in spine BMD (2.43%) compared to
CEE alone at the 0.3 mg/d dose (1.33%), the observed gains
in BMD did not diﬀer from the CEE alone at the 0.45mg/d
dose (2.09%). In addition, no diﬀerences in gains in hip
BMD were observed between any of the treatment groups.
Beneﬁts in spine BMD of up to 3.5% have also been reported
withtheuseoflow-doseHT(0.3mg/dCEE+2.5mg/dMPA)
in older postmenopausal women with low bone mass [44].
The search for the lowest eﬀective dose of HT has also
beeninvestigatedusingthetransdermaldeliverymethod[42,
47]. Using healthy postmenopausal women, both standard-
and low-dose transdermal 17β-estradiol with 100mg/d
micronized progesterone resulted in similar increases in
femur neck BMD (0.73% and 0.92%, respectively) after 18
months of treatment while the control group experienced a
signiﬁcant decrease in BMD (−2.23%) [42]. Another study
observed improvements of 1.65% and 4.08% in spine BMD
in healthy hysterectomized postmenopausal women that
were treated for 2 years with unopposed standard- and low-
dose transdermal 17β-estradiol, respectively [47].Testing the
eﬀectiveness of unopposed ultra-low-dose transdermal 17β-
estradiol, the Ultra-Low-dose Transdermal estRogen Assess-
ment(ULTRA)observeda2.6%increaseinBMDatthelum-
bar spine in nonhysterectomized postmenopausal women
after 2 years of treatment [39]. A non-hysterectomized
sample was used since endometrial safety was also examined.
Improvements in hip BMD and favorable changes in bio-
chemical markers of bone turnover (osteocalcin and bone-
speciﬁc alkaline phosphatase) were also observed from ultra-
low-dose [39].
While no large head-to-head studies have been con-
ducted between lower doses of HT and other pharma-
cologic agents used for the prevention or treatment of
postmenopausal bone loss, ultra-low dose transdermal HT
has also been shown to exert similar protection against
bone loss in the spine as the selective estrogen receptor
modulator,raloxifene[45].Ina2-yearRCTconductedin500
osteopenic postmenopausal women, 77.3% of those treated
with ultra-low-dose HT and 80.5% of those treated with
raloxifene did not experience bone loss at the lumbar spine.
Slight increases in total hip BMD were observed in both
the ultra-low-dose HT and raloxifene groups, and raloxifene
resulted in signiﬁcantly greater improvements in hip BMD
compared to ultra-low-dose HT. In addition, 63.8% of the
ultra-low-dose HT and 81.3% of the raloxifene groups did
not experience a loss of BMD at the hip. No diﬀerence in
fracture incidence was observed between both groups but
trials that are longer in duration are needed to adequately
determine whether lower doses and alternative methods of
delivery of HT modulate fracture risk [45].
6. SideEffects Associatedwith the Use of
Lower Doses andTransdermalHT
Studies have shown that the dose and formulation of HT
can be signiﬁcant factors that determine the safety proﬁle
of HT. In the transdermal delivery system, 17β-estradiol
is absorbed subcutaneously and is readily absorbed into
tissues as it circulates systemically before reaching the liver.
Because transdermal HT avoids ﬁrst-pass liver metabolism,
there is lower production of coagulation factors compared
to oral formulations, which may result in a lower risk for
cardiovascular events [48]. Thus, low-dose transdermal HT
has the potential to provide signiﬁcant beneﬁt to skeletal
health but with fewer side eﬀects than the conventionally
prescribed standard dose HT [49].
Evaluation of adverse events was included in the HOPE
trialwherebyadoseresponseinendometrialhyperplasiaand
vaginal bleeding was observed in women taking CEE alone,
with the greatest number of reported adverse eﬀects being
in the 0.625mg/d dose. A dose response in breast pain was
observed in women taking CEE + MPA, with the greatest
number of reported adverse eﬀects being in the 0.625mg/d6 Journal of Osteoporosis
Table 2: Selected studies on the eﬀect of lower doses of hormone therapy on bone metabolism in postmenopausal women.
Study Name Study Type
Sample Size, Mean Age in
Years (Range), and
Years since Menopause
Type of Therapy Dose Treatment
Duration
Results for BMD, BMC, or
Fracture Risk
ULTRA Trial
[39] RCT
417,
67 (60–80),
≥5 years
E2 patch or
placebo patch∗ E2: 0.014mg/day 2 years 2.1% greater LV BMD
versus placebo.
HOPE Trial
[40] RCT
822,
51.6 (40–65),
1t o≤4 years
CEE,
CEE + MPA, or
placebo∗
CEE: 0.625, 0.45, or
0.3mg/d
MPA: 2.5 or 1.5mg/d
2 years
1.33–3.46% increase in LV
BMD;
Approximately 1.5–3%
increase in hip BMD;
1.03–1.74% increase in
total BMC, with these
doses.
Gambacciani
et al, 2008
[41]
Open Trial
Sample size not provided,
57 (range not provided),
≥1 year
E2 +N A( o r a l )
or no
treatment∗
1mgE 2 +0 . 5m gN A
for 28d or 0.5mg E2
+ 0.25mg NA per day
2 years
2–5% increase in LV BMD;
1.8–2.8% increase in femur
neck BMD, with these
doses.
Garcia-P´ erez
et al, 2006
[42]
Transversal
Study
136, 53 for 0.05mg/d and
placebo groups to 56 for
0.025mg/d group (range not
provided),
≥1 year
E2 patch +
micronized
progesterone, or
placebo∗
E2: 0.05 or 0.025mg/d
progesterone:
100mg/d
18 months
0.73–0.92% increase in
femur neck BMD;
−0.35–0.87% change in LV
BMD, with these doses.
Gambacciani
et al, 2001
[43]
Open Trial 38,54 (45–56),
≥1 year CEE + MPA∗ CEE: 0.3mg/d
MPA: 2.5mg/d 2 years 2.7% increase in LV BMD.
CEE: Conjugated Equine Estrogen, MPA: Medroxyprogesterone Acetate, NA: Norethisterone Acetate, E2:1 7 β-estradiol, BMD: Bone Mineral Density, BMC:
Bone Mineral Content, and LV: Lumbar Vertebrae. ∗All subjects received additional supplementation with calcium alone or with vitamin D.
dose [40]. The ULTRA trial, which examined the eﬀects
of unopposed ultra-low-dose transdermal 17β-estradiol on
BMD and biochemical markers of bone turnover in non-
hysterectomized postmenopausal women, did not observe
higher incidences of endometrial hyperplasia compared to
the placebo group [39]. In addition, further examination
of the ULTRA trial by Grady et al. [50] demonstrated that
nonopposed ultra-low-dose transdermal 17β-estradiol does
not signiﬁcantly change breast density in postmenopausal
women. Nielsen et al. [51] observed that similar to ralox-
ifene, no signiﬁcant change in breast density in osteopenic
postmenopausal women with 2-year treatment with ultra-
low-dose transdermal 17β-estradiol. Whether no signiﬁcant
change in breast density from lower doses of ET ultimately
results in reduced incidence of breast cancer compared to
standard ET therapies is not yet known. Indeed, there is a
necessity for long-term trials to assess whether lower doses
of HT using alternative modes of delivery aﬀect disease risk
proﬁles.
7. Conclusion
The beneﬁt of HT for the prevention and treatment of post-
menopausal bone loss and for relief of vasomotor symptoms
iswellacknowledged.Thus,HTisanattractiveoptionforthe
treatment of postmenopausal-related symptoms. However,
due to its well-known ability to modulate physiology and
subsequentdiseaseriskinothertissues,thesafetyofHTmust
always be considered before it is prescribed. While standard-
dose HT through the oral delivery method is eﬀective against
both postmenopausal bone loss and vasomotor symptoms,
discrepancies in its safety have been noted between observa-
tional trials and RCTs. While review of the studies to date
reveals discrepancies among studies and limitations of trials
using standard doses of HT, emerging data suggests that HT
can be safe for younger postmenopausal women. Moreover,
lower doses of HT and alternative modes of delivery such as
the transdermal patch may be a safe alternative to standard
HT in protecting against postmenopausal bone loss while
relieving vasomotor symptoms. The dialogue regarding HT
should continue as ﬁndings from new studies using lower
dosesofHTandalternativemodelsofdeliveryarepublished.
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